Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854507 | 0.94 | BRD4 (0.48) | TNK2EGFRJAK3JAK2CSF1R | |
| SCHEMBL12854521 | 0.92 | EGFR (0.44) | FLT3BTKTNK2EGFRJAK3 | |
| SCHEMBL12854519 | 0.90 | NTRK1 (0.50) | FLT3BTKEGFRJAK3JAK2 | |
| SCHEMBL12854491 | 0.89 | TNK2 (0.48) | FLT3BTKTNK2EGFRJAK3 | |
| SCHEMBL12854492 | 0.88 | TNK2 (0.47) | FLT3BTKTNK2EGFRJAK3 | |
| SCHEMBL14481840 | 0.87 | FLT3 (0.48) | FLT3BTKTNK2EGFRJAK3 | |
| SCHEMBL12854498 | 0.87 | TNK2 (0.46) | FLT3BTKTNK2EGFRJAK3 | |
| SCHEMBL12854517 | 0.85 | BRD4 (0.46) | TNK2EGFRCSF1RPDGFRBPDGFRA | |
| SCHEMBL12854542 | 0.85 | NTRK1 (0.49) | FLT3BTKEGFRJAK3JAK2 | |
| SCHEMBL12854511 | 0.84 | JAK2 (0.57) | JAK3JAK2NTRK2BRD4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | FLT3 516/4885BTK 817/4885TNK2 39/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | FLT3 525/4885BTK 993/4885TNK2 68/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | FLT3 516/4885BTK 817/4885TNK2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.